0
Satsuma Pharmaceuticals, Inc. Banner Image

Satsuma Pharmaceuticals, Inc.

  • Ticker STSA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Satsuma Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in South San Francisco, California
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developingMore STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.
Satsuma Pharmaceuticals, Inc.

Most Recent Annual Report

Satsuma Pharmaceuticals, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports